Janus Henderson Group’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
Other funds holding RNAC
6CM
Janus Henderson Group's RNAC Position: Q3 2026 in Review
Janus Henderson Group increased its Cartesian Therapeutics (RNAC) stake by 2.8% in Q3 2026, buying an estimated $49.2K and bringing the position to 206,554 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1587.
Janus Henderson Group first reported a position in RNAC in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.09M in Q2 2026. 100 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.
- Janus Henderson Group held 206,554 shares of Cartesian Therapeutics worth $1.49M as of Q3 2026.
- Janus Henderson Group bought 5,649 Cartesian Therapeutics shares in Q3 2026, an estimated $49.2K.
- Cartesian Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q3 2026, its #1587 holding.
- Janus Henderson Group first reported a position in Cartesian Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Janus Henderson Group's Cartesian Therapeutics position peaked at $2.09M in Q2 2026.
- 100 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.
Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.